IP Library Granted Patent US 9,227,914
Granted Patent B2
US 9,227,914 · App. 14/640,711 · Granted Jan 5, 2016

Calcilytic compounds

Inventors: Robert W. Marquis (Collegeville, PA); Linda N. Casillas (Collegeville, PA); Joshi M. Ramanjulu (Collegeville, PA); James Francis Callahan (King of Prussia, PA)
Assignee: GlaxoSmithKline, LLC
C07C217/54C07C217/30C07C217/32C07C217/34C07C229/34C07C2102/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,227,914
App. No.
14/640,711
Granted
Jan 5, 2016
Kind
B2
Abstract

Novel calcilytic compounds and methods of using them are provided.

Claims (7)

1. A method of treating periodontal disease, which comprises the administration to a subject in need of treatment thereof an effective amount of a compound selected from: 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid and 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid ethyl ester; or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the compound administered is 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid.

3. The method according to claim 1 , wherein the compound administered is a pharmaceutically acceptable salt of the compound 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid.

4. The method according to claim 1 , wherein the compound administered is 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid hydrochloride.

5. The method according to claim 1 , wherein the compound administered is 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid ethyl ester.

6. The method according to claim 1 , wherein the compound administered is a pharmaceutically acceptable salt of the compound 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid ethyl ester.

7. The method according to claim 1 , wherein the compound administered is 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid ethyl ester hydrochloride.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2015
From: MARQUIS, ROBERT W.; CASILLAS, LINDA N; RAMANJULU, JOSHI M.; CALLAHAN, JAMES FRANCIS
To: SMITHKLINE BEECHAM CORPORATION
Reel/Frame 037111/0975 →
CHANGE OF NAME Recorded Nov 23, 2015
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 037151/0790 →
Continuity (7)
Continuation 14069447 · Nov 1, 2013
Continuation 13764126 · Feb 11, 2013
Continuation 12894644 · Sep 30, 2010
Continuation 12393284 · Feb 26, 2009
Division 10536416
Provisional Application 60429105 · Nov 26, 2002
Related Publication 20150183723A1 · Jul 2, 2015